Publications scientifiques Bordet

Publications scientifiques Bordet

  • Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.

  • Auteurs Classe JM, Meeus P, Hudry D, Wernert R, Quenet F, Marchal F, Houvenaeghel G, Bats AS, Lecuru F, Ferron G, Brigand C, Berton D, Gladieff L, Joly F, Ray-Coquard I, Durand-Fontanier S, Liberale G, Pocard M, Georgeac C, Gouy S, Guilloit JM, Guyon F, Costan C, Rousselet JM, de Guerké L, Bakrin N, Brument E, Martin E, Asselain B, Campion L, Glehen O
  • Revue Lancet Oncol
  • Date de publication 2024-12
Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial.
  • An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.

  • Auteurs Houda I, Bahce I, Dickhoff C, Kroese TE, Kroeze SGC, Mariolo AV, Tagliamento M, Moliner L, Brandão M, Pretzenbacher Y, Edwards J, Opitz I, Brunelli A, Guckenberger M, van Schil PE, Popat S, Blum T, Faivre-Finn C, de Ruysscher D, Remon J, Berghmans T, Dingemans AC, Besse B, Hendriks LEL
  • Revue Lung Cancer
  • Date de publication 2024-12
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.
  • Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours.

  • Auteurs Pellat A, Grinda T, Cresta Morgado P, Prelaj A, Miskovic V, Valachis A, Zerdes I, Martins-Branco D, Provenzano L, Spagnoletti A, Nader-Marta G, Wilson BE, Yang YH, Pentheroudakis G, Delaloge S, Castelo-Branco L, Koopman M
  • Revue ESMO Real World Data Digit Oncol
  • Date de publication 2024-12
Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours.
  • Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.

  • Auteurs De Jaeghere EA, Tuyaerts S, Van Nufel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Denys HG
  • Revue Cancer Immunol Immunother
  • Date de publication 2024-12
Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
Erasme hospital

Hôpital Erasme

Consultez toutes les publications scientifiques d'Erasme

Huderf hospital

Hôpital pédiatrique Reine Fabiola

Consultez toutes les publications scientifiques de l'Hôpital pédiatrique Reine Fabiola

Decorative image of doctor and patient

Toutes les publications scientifiques du H.U.B.

Consulter toutes les publications scientifiques du H.U.B.